Abstract
The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/β-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/β-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on β-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/β-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A et al. (2007a). Association of Wwox with ErbB4 in breast cancer. Cancer Res 67: 9330–9336.
Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y et al. (2005). WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65: 6764–6772.
Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LYCroce CM . (2007b). Inactivation of the Wwox Gene Accelerates Forestomach Tumor Progression in vivo. Cancer Res 67: 5606–5610.
Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky YCroce CM . (2004a). Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res 64: 8256–8261.
Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T et al. (2004b). Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA 101: 4401–4406.
Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y et al. (2007c). Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104: 3949–3954.
Barel P . (1993). Cellular Interactions In Development: A Practical Approach In: Hartley DA (ed) Oxford University Press: Oxford, 153–179.
Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K et al. (2001). WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61: 8068–8073.
Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM . (2000). WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140–2145.
Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M et al. (2007). Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 316: 1619–1622.
Brown AM . (2001). Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 3: 351–355.
Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB et al. (2001). Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 276: 3361–3370.
Chang NS, Schultz L, Hsu LJ, Lewis J, Su MSze CI . (2005). 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene 24: 714–723.
Clevers H . (2006). Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480.
Cong F, Schweizer L, Varmus H . (2004). Casein kinase Iepsilon modulates the signaling specificities of dishevelled. Mol Cell Biol 24: 2000–2011.
Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P et al. (2005). Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 438: 867–872.
Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E . (2002). Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21: 1832–1840.
Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N et al. (2005). WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA 102: 15611–15616.
Gan XQ, Wang JY, Xi Y, Wu ZL, Li YPLi L . (2008). Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol 180: 1087–1100.
Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM et al. (2006). Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res 66: 11585–11589.
Gonzalez-Sancho JM, Brennan KR, Castelo-Soccio LA, Brown AM . (2004). Wnt proteins induce dishevelled phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize beta-catenin. Mol Cell Biol 24: 4757–4768.
Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW et al. (2004). The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100: 1605–1614.
Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P et al. (2005). Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55: 471–478.
Herber B, Truss M, Beato M, Muller R . (1994). Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9: 1295–1304.
Hezova R, Ehrmann J, Kolar Z . (2007). WWOX, a new potential tumor suppressor gene. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151: 11–15.
Hino S, Kishida S, Michiue T, Fukui A, Sakamoto I, Takada S et al. (2001). Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol Cell Biol 21: 330–342.
Hino S, Michiue T, Asashima M, Kikuchi A . (2003). Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. J Biol Chem 278: 14066–14073.
Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K . (2007). Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13: 268–274.
Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA et al. (2005). Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24: 1625–1633.
Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T et al. (2003). Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1: 940–947.
Itoh K, Brott BK, Bae GU, Ratcliffe MJ, Sokol SY . (2005). Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling. J Biol 4: 3.
Kadoya T, Kishida S, Fukui A, Hinoi T, Michiue T, Asashima M et al. (2000). Inhibition of Wnt signaling pathway by a novel axin-binding protein. J Biol Chem 275: 37030–37037.
Kikuchi A, Kishida S, Yamamoto H . (2006). Regulation of Wnt signaling by protein–protein interaction and post-translational modifications. Exp Mol Med 38: 1–10.
Kishida M, Hino S, Michiue T, Yamamoto H, Kishida S, Fukui A et al. (2001). Synergistic activation of the Wnt signaling pathway by Dvl and casein kinase Iepsilon. J Biol Chem 276: 33147–33155.
Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M, Kikuchi A . (1999). DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol 19: 4414–4422.
Klimowski LK, Garcia BA, Shabanowitz J, Hunt DF, Virshup DM . (2006). Site-specific casein kinase 1epsilon-dependent phosphorylation of Dishevelled modulates beta-catenin signaling. FEBS J 273: 4594–4602.
Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H et al. (2004). The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10: 2459–2465.
Lallemand F, Seo SR, Ferrand N, Pessah M, L'Hoste S, Rawadi G et al. (2005). AIP4 restricts transforming growth factor-beta signaling through a ubiquitination-independent mechanism. J Biol Chem 280: 27645–27653.
Lee JS, Ishimoto A, Yanagawa S . (1999). Characterization of mouse dishevelled (Dvl) proteins in Wnt/Wingless signaling pathway. J Biol Chem 274: 21464–21470.
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y et al. (2000). Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262–4266.
Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM . (2003). WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100: 101–110.
Ludes-Meyers JH, Kil H, Bednarek AK, Drake J, Bedford MT, Aldaz CM . (2004). WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 23: 5049–5055.
Ludes-Meyers JH, Kil H, Nunez MI, Conti CJ, Parker-Thornburg J, Bedford MT et al. (2007). WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer 46: 1129–1136.
Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M et al. (2000). Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 60: 1683–1689.
Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE et al. (2005). Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89: 99–105.
Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC et al. (2000). A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60: 1690–1697.
Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D et al. (2001). WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98: 11417–11422.
Pimenta FJ, Gomes DA, Perdigao PF, Barbosa AA, Romano-Silva MA, Gomez MV et al. (2006). Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer 118: 1154–1158.
Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK . (2006). WWOX–the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol 32: 153–157.
Polakis P . (2000). Wnt signaling and cancer. Genes Dev 14: 1837–1851.
Qin HR, Iliopoulos D, Nakamura T, Costinean S, Volinia S, Druck T et al. (2007). WWOX suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res 5: 957–965.
Rain JC, Selig L, De Reuse H, Battaglia V, Reverdy C, Simon S et al. (2001). The protein-protein interaction map of Helicobacter pylori. Nature 409: 211–215.
Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK et al. (2000). Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 9: 1651–1663.
Shibamoto S, Higano K, Takada R, Ito F, Takeichi M, Takada S . (1998). Cytoskeletal reorganization by soluble Wnt-3a protein signalling. Genes Cells 3: 659–670.
Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H et al. (1999). Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J 18: 2823–2835.
Torres MA, Nelson WJ . (2000). Colocalization and redistribution of dishevelled and actin during Wnt-induced mesenchymal morphogenesis. J Cell Biol 149: 1433–1442.
Vojtek AB, Hollenberg SM . (1995). Ras-Raf interaction: two-hybrid analysis. Methods Enzymol 255: 331–342.
Wang X, Chao L, Jin G, Ma G, Zang Y, Sun J . (2009). Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumour Biol 30: 8–14.
Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K et al. (2003). An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63: 8629–8633.
Wharton Jr KA . (2003). Runnin with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol 253: 1–17.
Willert K, Jones KA . (2006). Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394–1404.
Yokoyama N, Yin DMalbon CC . (2007). Abundance, complexation, and trafficking of Wnt/beta-catenin signaling elements in response to Wnt3a. J Mol Signal 2: 11.
Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C et al. (2008). Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135: 367–375.
Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R et al. (2005). A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438: 873–877.
Acknowledgements
We are grateful to Dr Trevor Dale for donating HA-Dvl-2 (mouse) expression vector, Dr Akira Kikuchi for donating pCCN/Dvl-1 (human) and pEF-BOS-myc/Dvl-3 (human) plasmids, Dr Howe PH for donating pCDNA3-myc/Axin (human) and Dr Shinji Takada for donating mouse fibroblast L cells producing Wnt-3a and L cells stably transfected with the pGKneo plasmid. We thank Ivan Bièche and Christian Gespash for useful comments, Florence Copigny and Cédrick Lefol for excellent technical assistance, and Philippe Leclerc (IFR 93, kremelin Bicétre, France) for immunofluorescence analysis. This work was supported by a GenHomme Network Grant (02490-6088) to Hybrigenics and Institut Curie. We thank all the Hybrigenics staff for their contribution and the staff of the Drosoman laboratory, headed by Jacques Camonis and supported by Institut Curie.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bouteille, N., Driouch, K., Hage, P. et al. Inhibition of the Wnt/β-catenin pathway by the WWOX tumor suppressor protein. Oncogene 28, 2569–2580 (2009). https://doi.org/10.1038/onc.2009.120
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.120
Keywords
This article is cited by
-
WWOX binds MERIT40 and modulates its function in homologous recombination, implications in breast cancer
Cancer Gene Therapy (2023)
-
WWOX and metabolic regulation in normal and pathological conditions
Journal of Molecular Medicine (2022)
-
TGFα-EGFR pathway in breast carcinogenesis, association with WWOX expression and estrogen activation
Journal of Applied Genetics (2022)
-
In vitro and in silico assessment of the effect of WWOX expression on invasiveness pathways associated with AP-2 transcription factors in bladder cancer
BMC Urology (2021)
-
Pleiotropic tumor suppressor functions of WWOX antagonize metastasis
Signal Transduction and Targeted Therapy (2020)